Stay updated on Switch to Dolutegravir + Rilpivirine Clinical Trial
Sign up to get notified when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.
Latest updates to the Switch to Dolutegravir + Rilpivirine Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check22 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.3%
- Check29 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.2%
- Check37 days agoChange DetectedThe website has added a new last update posted on September 3, 2024, while the estimated last update posted from September 2, 2024, has been removed.SummaryDifference0.1%
- Check44 days agoChange DetectedThe study has transitioned from a planned to an ongoing phase, now assessing the long-term effects of switching to a two-drug regimen of dolutegravir (DTG) and rilpivirine (RPV) in HIV-1 infected adults, with results expected up to Week 148, while previous details about the study's initial aims and participant eligibility have been removed.SummaryDifference26%
- Check65 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.0%
Stay in the know with updates to Switch to Dolutegravir + Rilpivirine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.